ANRO
ANROHealthcareNASDAQBiotechnology · Last scanned May 28, 2026
Scan Results
Daily timeframe1 of 4 indicators bullish as of May 28
ANRO operates as a clinical-stage biopharmaceutical company in the United States. With a market capitalization of $709.6M, it sits in small-cap territory. The company's product pipeline includes ALTO-100, which is in Phase 2b clinical trial for the treatment of patients with bipolar depression (BPD).
Market Cap
$709.6M
Beta
—
P/E (TTM)
—
P/E (Fwd)
-5.89
EPS (TTM)
$-2.43
EPS (Fwd)
$-3.43
ROE
-38.9%
ROA
-21.7%
Cash
$263.8M
Total Debt
$21.9M
Free CF
-$39.9M
52W Change
683.7%
Annual Financials
Cash vs Debt
The balance sheet looks solid with $263.8M in cash comfortably exceeding the $21.9M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. Free cash flow is running at -$39.9M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. Return on equity stands at -38.9%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits.
With cash comfortably exceeding debt, ANRO has financial flexibility that may help navigate uncertain periods. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing ANRO.